Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids.

Authors: Ali, Mohamed; Raslan, Mohamed; Ciebiera, Michał; Zaręba, Kornelia; Al-Hendy, Ayman

Published In Expert Opin Drug Saf, (2022 Apr)

Abstract: INTRODUCTION: Uterine fibroids (UFs) are the most prevalent benign neoplastic threat originating from myometria of reproductive age women, with a profound financial load valued in hundreds of billions of dollars. Unfortunately, there is no curative treatment so far except surgery and available pharmacological treatments are restricted for short-term treatment options. Thus, there is a large unmet need in the UF space for noninvasive therapeutics. AREAS COVERED: The authors reviewed the literature available for the utility of gonadotropin-releasing hormone (GnRH) analogs in women with UFs. We also focused on clinical studies exploring the therapeutic benefits of novel oral non-peptide GnRH antagonists that were recently approved by the U.S. Food and Drug Administration (FDA) in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with UFs in premenopausal women. EXPERT OPINION: The results regarding the efficacy of new-generation oral GnRH-antagonists, such as elagolix, relugolix and linzagolix, are promising and offer potential prospect for the future therapy of UFs. However, these antagonists must be combined with hormonal add-back therapy to minimize the resultant hypoestrogenic side effects such as bone loss.

PubMed ID: 34612122 Exiting the NIEHS site

MeSH Terms: Carboxylic Acids/therapeutic use; Female; Gonadotropin-Releasing Hormone/analogs & derivatives*; Humans; Leiomyoma*/drug therapy; Pyrimidines; Uterine Neoplasms*/drug therapy

to Top